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Generation of functional neurons and glia from
multipotent adult mouse germ-line stem cells
Katrin Streckfuss-Bömeke a,1, Alla Vlasov a,1, Swen Hülsmann b,
Dongjiao Yin a, Karim Nayernia c,2, Wolfgang Engel c,
Gerd Hasenfuss a,⁎, Kaomei Guan a,⁎a Department of Cardiology and Pneumology, Georg-August-University of Göttingen, 37075 Göttingen, Germany
b Department of Neuro- and Sensory Physiology, DFG Research Center of Molecular Physiology of the Brain,
Georg-August-University of Göttingen, 37075 Göttingen, Germany
c Institute of Human Genetics, Georg-August-University of Göttingen, 37075 Göttingen, GermanyReceived 17 April 2008; received in revised form 10 September 2008; accepted 14 September 2008Abstract Recently, we reported the successful establishment of multipotent adult germ-line stem cells (maGSCs) from
cultured adult mouse spermatogonial stem cells. Similar to embryonic stem cells, maGSCs are able to self-renew and
differentiate into derivatives of all three germ layers. These properties make maGSCs a potential cell source for the treatment
of neural degenerative diseases. In this study, we describe the generation of maGSC-derived proliferating neural precursor
cells using growth factor-mediated neural lineage induction. The neural precursors were positive for nestin and Sox1 and could
be continuously expanded. Upon further differentiation, they formed functional neurons and glial cells, as demonstrated by
expression of lineage-restricted genes and proteins and by electrophysiological properties. Characterization of maGSC-
derived neurons revealed the generation of specific subtypes, including GABAergic, glutamatergic, serotonergic, and
dopaminergic neurons. Electrophysiological analysis revealed passive and active membrane properties and postsynaptic
currents, indicating their functional maturation. Functional networks formed at later stages of differentiation, as
evidenced by synaptic transmission of spontaneous neuronal activity. In conclusion, our data demonstrate that maGSCs
may be used as a new stem cell source for basic research and biomedical applications.
© 2008 Elsevier B.V. All rights reserved.Introduction
Previous studies showed that embryonic stem cell (ESC)-
derived neural precursors (Reubinoff et al., 2001; Zhang et
al., 2001), mature neurons (Lee et al., 2000; Kim et al.,
2002; Takagi et al., 2005; Roy et al., 2006), and glia (Brustle⁎ Corresponding authors. Fax: +49 551 3922953.
E-mail address: kguan@med.uni-goettingen.de (K. Guan).
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2 Present address: Institute of Human Genetics, University of
Newcastle upon Tyne, Newcastle upon Tyne NE1 3BZ, UK.
1873-5061/$ – see front matter © 2008 Elsevier B.V. All rights reserved
doi:10.1016/j.scr.2008.09.001et al., 1999) might provide new cell sources for cellular
therapy of neurodegenerative diseases. These neural popu-
lations are characterized by an expression pattern of genes
and proteins specific for neural progenitors, mature neurons,
and glial cells. In addition, synaptic properties of these cells
confirming their function in vitro were described (Lee et al.,
2000). Several studies showed that ESC-derived cells can be
successfully used to treat neural diseases in animal models.
Dopamine-synthesizing neurons derived from both mouse
and human ESCs were demonstrated to integrate function-
ally into host tissue in a rodent model of Parkinson disease
(Kim et al., 2002; Perrier et al., 2004; Roy et al., 2006)..
Figure 1 Differentiation of maGSCs into neural cells. (A) A
schematic procedure of the serial selection and differentiation
of neural cells from undifferentiated maGSCs. Undifferentiated
maGSCs were expanded on MEFs in ESC medium (Stage 1). Cell
aggregates were generated after cultivation of MEF-eliminated
maGSCs in suspension in NSC medium for 2 days (Stage 2). After
cell aggregates were plated, neural progenitors were selected in
serum-free NSC medium in the presence of bFGF and EGF for 10–
18 days (Stage 3). The induction of differentiation was achieved
by switching the culture medium to N2B27-I medium with bFGF.
FGF8b and Shh were added for the first 2 days (Stage 4). Finally,
maturation of neurons and glial cells was achieved by cultivation
for another 6 to 20 days in N2B27-I medium with bFGF (Stage 5).
(B) Undifferentiated maGSCs cultured on MEFs (Stage 1). (C) Cell
aggregates after 2-day suspension culture (Stage 2). (D) Neural
progenitors after 17-day selection (Stage 3). (E) Differentiated
culture 1 day after treatment with FGF8b and Shh (Stage 4). (F)
Mature neurons at day 10 after withdrawal of FGF8b and Shh
(Stage 5). Scale bars, 25 μm (B, C), 50 μm (D–F).
140 K. Streckfuss-Bömeke et al.Despite the potential of ESCs as an unlimited cellular source
for therapeutic application, ethical and immunological
problems limit their widespread use.
Adult somatic stem cells may constitute an alternative
cell source for therapeutic approaches. For example, a
neural stem cell (NSC)-like population was generated from
adult human bone marrow stromal cells, although dopami-
nergic neurogenic activity was not observed (Hermann et al.,
2004). Other studies reported that bone marrow-derived
multipotent adult progenitor cells from mouse and rat were
able to differentiate into cells with neuroectoderm char-
acteristics (Jiang et al., 2002). Although these adult-derived
stem cells show some neurogenic activity, it appears to be
somewhat limited compared to ESCs.
We have recently shown that isolated spermatogonial
stem cells from adult mouse testis are able to acquire ESC
properties following in vitro cultivation. These multipotent
adult germ-line stem cells, which we have designated
maGSCs, have the potential to give rise to cell types of all
three germ layers, including neural cells (Guan et al., 2006).
In addition, we reported that maGSCs could differentiate
into functional cardiomyocytes similar to those derived from
mouse ESCs (Guan et al., 2007). In this study we show that
maGSCs are able to differentiate into neural populations in
vitro. The resulting cells exhibit structural and functional
characteristics of neural progenitors, mature neurons,
astrocytes, and oligodendrocytes.
Results
Standardized protocols for differentiation of
maGSCs into neural lineages
To induce maGSCs to differentiate into functional neurons
and glial cells, we employed a modified growth factor-
mediated protocol established for neural differentiation of
mouse ESCs (Ying and Smith, 2003; Conti et al., 2005). The
protocol involves five stages (Fig. 1A). First, undifferentiated
maGSCs (Fig. 1B) were expanded on mitomycin C-inactivated
mouse embryonic fibroblasts (MEFs) in ESC medium (Stage 1,
Fig. 1A). Prior to induction of neural differentiation, MEFs
were eliminated by using preplating methods. MEF-elimi-
nated maGSCs were cultured in suspension as cell aggregates
(Fig. 1C) for 2 days under serum-free and feeder-free
conditions in NSC medium supplemented with basic fibro-
blast growth factor (bFGF) and epidermal growth factor
(EGF; Stage 2, Fig. 1A). After the aggregates were plated on
gelatin-coated culture dishes, neural precursors were
selected in NSC medium for 10–18 days (Stage 3, Fig. 1A).
At this point, a proportion of the cells detached from the
plate, and those remaining changed their morphology from
tightly packed cells to small, elongated, sharp-edged, and
flattened cells that were arranged as rosettes, the typical
morphology of neural progenitors (Fig. 1D). To induce
functional neurons, these progenitors were cultured in
N2B27-I medium supplemented with bFGF, FGF8b, and
sonic hedgehog (Shh) for 2 days (Stage 4, Fig. 1A). Previous
studies indicated that FGF8b and Shh enhanced the produc-
tion of dopaminergic and serotonergic neurons (Ye et al.,
1998; Roy et al., 2006). Indeed, polar cells with short
dendrites and axons were apparent 1 day after the initiationof Shh and FGF8b treatment (Fig. 1E). Subsequent with-
drawal of FGF8b and Shh and further cultivation in N2B27-I
with bFGF for 6 to 20 days resulted in maturation of
functional neurons and glial cells (Stage 5, Fig. 1A). Many
cells exhibited a polarized morphology with elongated,
Figure 2 RT-PCR analysis of transcription factors and genes
essential for undifferentiated maGSCs and neural lineages.
Analyses were performed in undifferentiated maGSCs at Stage
1, neural progenitors at Stage 3 (13 days in NSC medium with EGF
and bFGF), and differentiated neurons and glia at Stage 4 (2-day
Shh and FGF8b treatment) and Stage 5 (17 days after withdrawal
of Shh and FGF8b). Mouse embryonic fibroblasts (MEFs) were
used as the negative control. syn, synaptophysin; GFAP, glial
fibrillary acidic protein; GLT1, glutamate transporter-1; SerT,
serotonin transporter; GAD65, glyceraldehyde-3-phosphate
dehydrogenase 65 kDa; TH, tyrosine hydroxylase; D2R-L, long
isoform of dopamine receptor D2; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase.
141Generation of neurons from mouse stem cellsthickened axons 10 days after Shh and FGF8b withdrawal
(Fig. 1F).
Characterization of Stage 2 and 3 cultures:
formation of maGSC-derived neural progenitors
Stage 2 culture conditions were based on the observation
that neurogenic differentiation of ESCs occurs in the absence
of serum and/or the presence of growth factors in multi-
cellular aggregates (Wiles and Johansson, 1999), in suspen-
sion culture (Tropepe et al., 2001), or in adherent monolayer
culture (Ying and Smith, 2003). At Stage 2, MEF-eliminated
maGSCs formed cell aggregates (Fig. 1C), which were much
smaller than those formed in serum-containing medium
(data not shown). In Stage 3 cultures, RT-PCR analysis
revealed decreased expression of Oct3/4 and Nanog (which
are often used as markers for pluripotent stem cells)
compared to undifferentiated maGSCs at Stage 1 (Fig. 2).
Concurrently, expression of the transcription factor Sox2
(characteristic for both undifferentiated stem cells and
neural progenitors) was not altered (Fig. 2). In contrast, the
expression of nestin (an immature neural marker) was
significantly increased in Stage 3 cultures compared to
undifferentiated maGSCs at Stage 1 (Fig. 2). In addition, the
transcription factor Mash1 (required for the development of
different neural cell types) was also highly expressed at the
same stage (Fig. 2). These mRNA data were supported by
double immunofluorescence staining using antibodies
against Oct3/4 and nestin (Fig. 3). In undifferentiated
maGSC cultures at Stage 1, 89.1% of cells exhibited Oct3/4
nuclear immune reactivity (Figs. 3B and 3E); in contrast the
number of Oct3/4-positive cells was reduced to 5.2%
(Pb0.001) in Stage 3 cultures (Figs. 3A and 3E). Furthermore,
only 6.2% of cells were positive for nestin, mainly in Oct3/4-
negative cells, in undifferentiated maGSC cultures at Stage 1
(Figs. 3A and 3E). The increase in nestin-positive cells (Figs.
3B and 3E) up to 87.9% (Pb0.001) in neural progenitors of
Stage 3 cultures was inversely related to the level of Oct3/4
immune reactivity (Figs. 3B and 3E). Since the Oct3/4
antibody used in the study is a goat polyclonal antibody, to be
sure of the specificity of the results we included control
experiments. As shown in Fig. 3D, no specific staining was
observed in undifferentiated maGSCs when the Oct3/4
antibody was replaced with normal goat serum, indicating
the specificity of the method. In addition, we performed
Western blot to detect Oct3/4 proteins in undifferentiated
maGSCs as well as in MEFs and found a single band of 46 kDa
in maGSCs, but not in MEFs, indicating the specificity of the
antibody (Supplementary Fig. 1).
Although nestin is expressed most prominently in tissues
of the neural system during embryogenesis, suggesting that
nestin-positive cells are critical for embryonic neural
development, its expression is also present in other
embryonic and fetal cell types, such as somatic mesodermal
cells (Lendahl et al., 1990; Sejersen and Lendahl, 1993; see
also review by Wiese et al., 2004). Therefore, we further
characterized the Stage 3 cultures using another more
specific marker, Sox1. Sox1, a SRY-related transcription
factor, is confined to the neuroepithelium of the neural
plate in the early mouse embryo and dividing neural
progenitors derived from mouse ESCs (Li et al., 1998;
Pevny et al., 1998). We found that over 95% of nestin-positive neural progenitors expressed Sox1 in Stage 3
cultures (Fig. 4A). For double immunostaining with nestin
and Sox1, to exclude the cross-reactivity of second anti-
bodies, we used our neural progenitor cultures at Stage 3 as
controls. Two coverslips were treated with nestin and Sox1
antibodies separately, but incubated with both Alexa Fluor
488 donkey anti-mouse IgG (for nestin) and Cy3-conjugated
donkey anti-chicken IgY (for Sox1) together. No red signals
were detected when the culture was stained with nestin
antibody (Fig. 4C). No green signals were detected when the
culture was stained with Sox1 antibody (Fig. 4D). These data
indicate that there is no cross-reactivity of either second
antibody.
Thus, cultivation of maGSCs in serum-free NSC medium
supplemented with bFGF and EGF resulted in the efficient
142 K. Streckfuss-Bömeke et al.induction of neural progenitors. Furthermore, high levels of
cell cycle activity were apparent in Stage 3 neural precursor
cultures, as demonstrated by the expression of the pro-
liferation marker Ki67 (Figs. 5D–5F), similar to Stage 1undifferentiated maGSCs (Figs. 5A–5C). In addition, we
found that a small fraction of the cells (8.3%; Figs. 3C and 3F)
expressed the structural marker βIII-tubulin, which is
characteristic of immature neurons (Lee et al., 1990).
143Generation of neurons from mouse stem cellsCharacterization of Stage 4 and 5 cultures:
formation of mature neurons and glial cells
To induce differentiation and maturation of functional
neurons and glial cells, nestin/Sox1-positive neural progeni-
tors (from Stage 3) were cultured in N2B27-I medium with
bFGF (i.e., Stage 4 and 5 cultures). The ventral midbrain
patterning factors FGF8b and Shh were applied for 2 days
(Stage 4 cultures). High expression levels of the gene
encoding the neuronal marker synaptophysin (syn; a specific
protein of the synaptic vesicle membrane) were detected in
the cultures after the 2-day treatment with FGF8 and Shh
(Stage 4) and were retained up to 17 days after withdrawal of
Shh and FGF8b (Stage 5). In contrast, only low levels of
synaptophysin expression were detected in neural progeni-
tors (Stage 3, see Fig. 2).
Robust expression of the transcription factors Mash1 and
Olig2 (which control specification and differentiation of
oligodendrocytes) was observed in Stage 4 and 5 cultures,
indicating that the neural precursors also had the potential
to differentiate into glial cells. This was supported by the
observation that maximal expression of glial fibrillary acidic
protein (GFAP) and the glial glutamate transporter-1 (GLT1;
specific for astrocytes) occurred in Stage 4 and 5 cultures
(Fig. 2).
Mature neuronal cells are specified by the production of
different neurotransmitters. To demonstrate the maturation
of neurons in our culture system, we analyzed the expression
of genes encoding serotonin (a transmitter found in ventral
hindbrain neurons and specific for serotonergic neurons)
transporter (SerT), glutamic acid decarboxylase (GAD65; the
rate-limiting enzyme in GABA biosynthesis), tyrosine hydro-
xylase (TH; an enzyme required for the biosynthesis of
dopamine), and the long isoform of dopamine receptor D2
(D2R-L) during differentiation (Fig. 2). Our data showed an
increased expression of all genes in cultures at Stage 4 in
comparison to neural precursor cultures at Stage 3. Expres-
sion persisted for as long as 17 days after FGF8b and Shh
withdrawal (Stage 5; Fig. 2), the latest time point analyzed.
In our study, we found low expression levels of genes
encoding synaptophysin, GFAP, and SerT in undifferentiated
maGSCs at Stage 1, indicating that a small part of maGSCs
spontaneously differentiate under the current culture con-
ditions in vitro. This is in line with the detection of nestin-
positive cells in undifferentiated maGSCs at Stage 1 (Figs. 3A
and 3E).
Neurogenic and glial differentiation were further con-
firmed by immunostaining for βIII-tubulin, synaptosome-
associated protein 25 kDa (SNAP25; a marker of mature
neurons), the astrocyte marker GFAP, and the oligodendro-
cyte markers oligodendrocyte marker 1 (O1) and NG2, the
chondroitin sulfate proteoglycan (Fig. 6). An increasedFigure 3 Neural progenitor differentiation of maGSCs. (A) Strong
undifferentiated maGSCs at Stage 1, in contrast to (B and C) low exp
bFGF). Few nestin-positive cells (green) in undifferentiated maGSCs a
Few βIII-tubulin-positive neurons (green) were found in Stage 3 cultu
undifferentiated maGSC cultures when the Oct3/4 antibody was repla
diamino-2-phenylindole (DAPI; A–D, blue). (E and F) Quantitative
undifferentiated maGSCs at Stage 1 as well as in differentiated cult
FGF8b). ⁎⁎⁎Pb0.001. Scale bars, 25 μm.number of βIII-tubulin-positive cells (38%) were observed in
Stage 5 cultures in comparison to Stage 3 cultures (Fig. 3F).
Double immunostaining of βIII-tubulin and SNAP25 revealed
that 43% of the cells were positive either for βIII-tubulin or
for SNAP25 (Fig. 6C). Separately, 38% of cells were positive
for βIII-tubulin (Fig. 6A) and 11.5% of cells were positive for
SNAP25 (Fig. 6B). In addition, the multipolar cells with short
thin axons (characteristic morphology of cultured glial cells)
observed in Stage 5 were positive for GFAP (Fig. 6D), O1 (Fig.
6E), and NG2 (Figs. 6F and 6G). Quantitative analyses
revealed that, in addition to the presence of βIII-tubulin-
and SNAP25-labeled neurons, 33.5% of the cells in Stage 5
cultures were positive for GFAP. Whereas 20.2% of the cells
were positive for O1, only 11.7% were positive for NG2, an
antigen typically detected in oligodendrocyte precursors.
NG2-positive cells showed two cellular morphologies: “pro-
genitor” morphologic appearance (Fig. 6F) and “differen-
tiated” stellate “synantocytes” (Fig. 6G). These data
indicate that maGSC-derived neural progenitors, when
cultured in neural differentiation medium, can differentiate
into neurons and glial cells with a high efficiency.
We still found, however, Sox1-positive neural progenitors
in Stage 5 cultures with an efficiency of 20.3% that were also
positive for nestin (Fig. 4B). Double immunostaining using
antibodies against Sox1 and βIII-tubulin showed that some of
the Sox1-positive cells were positive for βIII-tubulin,
indicating they were immature neurons. In addition, only a
very small number (0.8%) of Oct3/4-positive cells were
observed in Stage 5 cultures (Fig. 3F).
Furthermore, the percentage of serotonergic, GABAergic,
or dopaminergic neurons was determined. Double immuno-
fluorescence using antibodies against serotonin, GAD65/67,
or TH, counterstained with the neuronal marker βIII-tubulin,
revealed that almost all serotonin- (Fig. 7A), GAD65/67- (Fig.
7B), and TH-labeled cells (Fig. 7C) were positively stained for
βIII-tubulin (Figs. 7A–7C). Since the antibodies against
serotonin, GAD65/67, and TH used in the study are rabbit
polyclonal antibodies, to be sure of the specificity of the
results we included control experiments. As shown in Fig. 7D,
no specific staining was observed in differentiated neurons at
Stage 5 when the primary antibodies were replaced with
normal rabbit serum, indicating the specificity of the
method. For double immunostaining with βIII-tubulin and
serotonin, GAD65/67, or TH, respectively, to exclude the
cross-reactivity of second antibodies, we used our differ-
entiated neuronal cultures at Stage 5 as controls. Two
coverslips were given βIII-tubulin and TH antibodies sepa-
rately, but incubated with both Alexa Fluor 488 donkey anti-
mouse IgG (for βIII-tubulin) and Cy3-conjugated goat anti-
rabbit (for TH) together. No red signals were detected when
the culture was stained with βIII-tubulin antibody (Fig. 7E).
No green signals were detected when the culture was stainedOct3/4-positive signals (red) were detected in the nucleus of
ression in Stage 3 cultures (10 days in NSC medium with EGF and
t Stage 1 (A) increased to a higher number in Stage 3 cultures (B).
res (C). (D) No specific Oct3/4-positive signals were observed in
ced by normal goat serum. The cell nuclei were stained with 4,6-
analysis of Oct3/4-, nestin-, and βIII-tubulin-positive cells in
ures at Stage 3 and Stage 5 (7 days after withdrawal of Shh and
Figure 4 Characterization of neural progenitors by immunostaining of Sox1 and nestin. (A) Nestin-positive cells (green) at Stage 3
were also positive for the neural progenitor marker Sox1 in the nucleus (red). (B) A few nestin- (green) and Sox1-positive (red) neural
progenitors were found in Stage 5 cultures. (C, D) Neural progenitors at Stage 3 were stained with nestin (C) and Sox1 (D) antibodies
separately, but incubated with both Alexa Fluor 488 donkey anti-mouse IgG (specific for nestin) and Cy3-conjugated donkey anti-
chicken IgY (specific for Sox1) together. No red signals were detected when the culture was stained with nestin antibody (C). No green
signals were detected when the culture was stained with Sox1 antibody (D). The cell nuclei were stained with DAPI (blue). Scale bars,
50 μm.
144 K. Streckfuss-Bömeke et al.with TH antibody (Fig. 7F). Similar data were obtained when
serotonin or GAD65/67 and βIII-tubulin antibodies were
applied (data not shown). These data indicate that there is
no cross-reactivity of either second antibody.
Additionally, we found dopamine transporter (DAT)-
positive dopaminergic neurons (Fig. 7G) as well as dopamineβ-hydroxylase (DBH)-positive noradrenergic neurons (Fig.
7H) in Stage 5 cultures. Quantitative analysis revealed
a significant increase in serotonin-positive neurons,
from 3.9±0.3% of all βIII-tubulin-positive cells at Stage 4 to
36.1±6.5% at Stage 5. The number of GAD65/67-labeled cells
increased from 4.0±0.6 to 14.5±2.9%. TH-positive cells were
Figure 5 Immunostaining of Ki67 in undifferentiated maGSCs at Stage 1 and maGSC-derived neural progenitors at Stage 3. Strong
Ki67-positive signals (green) were detected (A–C) in the nucleus of undifferentiated maGSCs at Stage 1 and (D–F) in maGSC-derived
neural progenitors at Stage 3 (10 days in NSC medium with EGF and bFGF). The cell nuclei were stained with DAPI. Scale bars, 25 μm.
145Generation of neurons from mouse stem cellsincreased from 4.9±0.5 to 16.0±4.6%. To study the effect of
2-day treatment with FGF8b and Shh on the induction of TH
and serotonin neurons, we performed control experiments in
the absence of FGF8b and Shh. We found a 65% reduction in
TH-positive cells (about 5% of TH-positive cells in the control
group) in the absence of FGF8b and Shh in Stage 5 cultures.
However, we did not observe a significant difference in
serotonin-positive cells in the absence of FGF8b and Shh.
These data show that in the presence of growth factors and
specific signaling molecules, maturation and survival of
serotonergic, GABAergic, and dopaminergic neurons were
induced at the late differentiation stages in our cultures.
Electrophysiological analysis of maGSC-derived
neurons and glial cells
For unequivocal characterization of neurogenic differentia-
tion in maGSC-derived cells, we analyzed a total number of
148 cells (Stage 5, days 8–19 after FGF8b and Shh with-
drawal) in vitro using whole-cell recordings. We first
employed voltage-clamp recordings to determine current–
voltage (I/V) relations. Cells were voltage clamped to−70 mV and stepped to potentials ranging from −150 to
+40 mV using 10-mV increments for 50 ms, while correspond-
ing currents were recorded (Fig. 8). The resulting I/V
relationships identified four distinct populations of maGSC-
derived neural cells. The first population of the cells (n=63)
showed electrophysiological properties resembling those of
neuronal or glial progenitor cells (Figs. 8A–8C). These cells
were characterized by an outwardly rectifying I/V relation-
ship. The resting membrane potential was —40.3±2.1 mV
and the input resistance was 706.2±81.9 MΩ. No voltage-
activated fast inward currents were visible using the
standard voltage step protocol.
The second population of cells (n=17) exhibited I/V
relationships similar to those of the progenitor cell popula-
tion described above. However, when subjected to the online
leak subtraction analysis, a small transient inward current
activating (−254.1±48.9 pA) at −50 mV was apparent. This
characteristic indicates the expression of voltage-gated
sodium channels. The resting membrane potential in this
population was −39.7±3.9 mV, while the input resistance of
748.6±199.9 MΩ was rather variable. These data suggest
that the second population of cells were immature neurons.
Figure 6 Characterization of maGSC-derived neuronal and glial cells at Stage 5. (A–C) Partial colocalization of βIII-tubulin (A and C,
green) and SNAP25 (B and C, red) in maGSC-derived neurons at day 7 after withdrawal of Shh and FGF8b. (D–G) Astrocytes and
oligodendrocytes were identified by immunostaining of GFAP (D), O1 (E), and NG2 (F, G). The cell nuclei were stained with DAPI. Scale
bars, 25 μm.
146 K. Streckfuss-Bömeke et al.The third population of cells (n=18) had characteristics
of mature neurons with a rapidly activating and inactivating
inward current elicited by depolarization to −50 mV and
above (Figs. 8D–8F). These transient inward currents were
followed by outwardly rectifying currents with an activation
threshold of about −40 mV. The reversal potential of the
fast inward current was positive to +20 mV, indicating the
presence of voltage-gated Na+ channels. The mean ampli-
tude of the sodium current was −780.1±138.8 pA, which
was significantly larger than that in the progenitor cell
population (Pb0.001). Interestingly, the input resistance
(1681.5±248.7 MΩ) of these neurons was also higher
(Pb0.001), while the resting potential (−32.8±3.2 mV)
was similar.
The fourth population of the cells had characteristics of
glial cells (n=50). These cells showed almost symmetrical,
inwardly and outwardly directed currents resulting in a linear
I/V relationship (Figs. 8G–8I). The resting membrane
potential in this population was −61.6±2.7 mV. Togetherwith the low input resistance (154.0±32.0 MΩ), this is
indicative of a high resting potassium conductance. The
difference in both parameters was significant compared to
both neurons and progenitor cells (Pb0.001).
We then determined if the expression of voltage-
activated sodium channels in maGSC-derived neurons was
strong enough to allow the generation of action potentials
(APs). Depolarizing current steps (0.1–1 nA) were applied in
the current clamp mode. Seven of nine tested neurons
showed at least a single AP after depolarization for 1 s
(current rejection of 50 pA). Whereas three neurons showed
phasic discharge of two to four APs during the persistent
depolarization, one cell showed a non-inactivating train of
APs during the entire depolarization (Fig. 8J). Neurons
derived from maGSCs were further analyzed to ascertain
their ability to form integrated synaptic networks. Post-
synaptic currents were recorded at a holding potential (Vhold)
of −70 mV. Postsynaptic currents of various size and
frequency were detected in roughly 50% (nf9) of the mature
147Generation of neurons from mouse stem cellsneurons (Fig. 8K). Spontaneous APs triggered by postsynaptic
potentials were observed in two cells (Fig. 8L), indicating
that maGSC-derived neurons were able to integrate func-
tionally in synaptic networks in vitro. To identify glutamateFigure 7 (A–C) Specification of maGSC-derived neurons. Sero
differentiated βIII-tubulin-positive neurons at Stage 5 (6 days afte
observed in Stage 5 cultures when the antibodies against serotonin, G
Stage 5 cultures in the absence of FGF8b and Shh were stained with
with both Alexa Fluor 488 donkey anti-mouse IgG (specific for βIII-tu
together. No red signals were detected when the culture was staine
when the culture was stained with TH antibody (F). (G) DAT- and (H
shows cell nuclei. Scale bars, 25 μm.receptors functionally, glutamate was applied locally and the
effect on membrane current was recorded at various
membrane potentials (−80 to +60 mV, 20-mV increment).
The I/V relationship revealed that glutamate applicationtonin- (A), GAD65/67- (B), and TH-positive neurons (C) in
r withdrawal of Shh and FGF8b). (D) No positive signals were
AD65/67, or TH were replaced by normal rabbit serum. (E and F)
βIII-tubulin (E) and TH (F) antibodies separately, but incubated
bulin) and Cy3-conjugated goat anti-rabbit IgG (specific for TH)
d with βIII-tubulin antibody (E). No green signals were detected
) DBH-positive neurons found in Stage 5 cultures. DAPI staining
Figure 7 (continued).
148 K. Streckfuss-Bömeke et al.elicited voltage-dependent currents reversing at 0 mV,
indicating the presence of excitatory glutamate receptors
on maGSC-derived neurons (n=3; Figs. 8M–8O).Discussion
In this study we describe an in vitro growth factor-
mediated differentiation procedure for the generation of
neural populations from mouse maGSCs with a highFigure 8 Electrophysiological characterization of neural cells in
currents (B, E, and H) recorded in response to a voltage step protoc
neuron- (D), or a glial-like cell (G), respectively. Averaged I/V curves
points indicated by the open (steady state) and filled circle (initia
potentials during depolarization. The neuron shown fires a train o
injection of 50 pA). The injection of negative current results in a p
membrane resistance (see Results). (K–O) Integration of maGSC-deri
spontaneous postsynaptic currents (Vhold=−70 mV; K). Spontaneous A
glutamate receptors in a maGSC-derived neuron. Membrane currents
10-mV increments, Vhold=−70 mV) in the cell (M). Membrane curre
glutamate recorded from the cell shown in M (N). The I/V relationshi
of different cells (n=3) were normalized to the respective peak ampefficiency. Neural precursors can be generated and
expanded in culture and, following additional differentia-
tion, are capable of generating neurons (GABAergic,
glutamatergic, serotonergic, and dopaminergic neurons)
and glial cells (astrocytes and oligodendrocytes). Electro-
physiological analysis confirmed functional neuronal
maturation and revealed the formation of integrated neural
networks.
The notion of cell replacement therapy to treat
neurodegenerative diseases is not new. There are nowStage 5 cultures. (A–I) Exemplary original traces of membrane
ol (−150 to +40 mV, 10-mV increments) for a progenitor- (A), a
from four cells of each type are shown in C, F, and I for the time
l response). (J) maGSC-derived neurons are able to fire action
f action potentials (APs) after depolarization for 1 s (current
ronounced hyperpolarization of the neuron, reflecting the high
ved neurons into synaptic networks. Exemplary original traces of
Ps triggered by postsynaptic potentials (L). (M–O) Expression of
recorded in response to a voltage step protocol (−150 to +40 mV,
nts at different membrane potentials induced by application of
p of the glutamate-induced current is shown in O. The responses
litudes at −60 mV and averaged. Scale bars, 10 μm (A, D, and G).
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transplantation can be an effective strategy for cellular
repair and functional recovery in animal models of
neurodegenerative diseases (see reviews Dunnett, 2000;
Dunnett and Rosser, 2007; Geraerts et al., 2007; Parish and
Arenas, 2007). However, the limited availability of fetal
tissues, combined with the variable clinical outcomes
observed to date, has prompted a search for alternative
sources of donor cells for therapeutic intervention. Several
types of stem cells, including ESCs, NSCs, and stem cells
from bone marrow and umbilical cord, have been investi-
gated with respect to their utility as a source of cells for
transplantation in Parkinson or Huntington diseases (see
reviews by Snyder and Olanow, 2005; Dunnett and Rosser,
2007).
ESCs are currently thought to be the best candidate for
transplantation in neurodegenerative diseases because of
their ability to yield large numbers of cells that can be
directed to differentiate into neural progenitors, as well as
functional neurons and glial cells (Brustle et al., 1999; Lee et
al., 2000; Reubinoff et al., 2001; Zhang et al., 2001; Kim et
al., 2002; Takagi et al., 2005; Roy et al., 2006). However, the
use of human ESCs has encountered opposition that has led to
considerations regarding ethical and immunological pro-
blems. Therefore, it is desirable to identify an alternative
stem cell population with differentiation potential similar to
that of ESCs.
Our results show that mouse maGSCs (derived from
cultured adult spermatogonial stem cells) exhibit neurogenic
activity similar to that seen with ESCs. When maGSCs were
cultured in NSC medium supplemented with bFGF and EGF
(the medium suitable for proliferation and survival of NSCs)
they differentiated into neural progenitors expressing the
neuroepithelial markers nestin and Sox1 with a high
efficiency. This result is consistent with data obtained from
ESC-derived neuroepithelial precursors (Zhang et al., 2001;
Conti et al., 2005). We also found that neural progenitors
derived from maGSCs can be continuously expanded in the
presence of EGF and bFGF. This is in line with previous
findings from ESC-derived neural progenitors (Conti et al.,
2005). Upon differentiation in N2B27-I medium supplemen-
ted with bFGF as described previously for ESCs (Ying and
Smith, 2003), maGSC-derived progenitors developed into
functional neurons, astrocytes, and oligodendrocytes. Quan-
titative analyses showed that 43% of the total cell population
stained for the neuronal markers SNAP25 and/or βIII-tubulin,
33.4% for the astrocyte-specific marker GFAP, 11.7% for the
oligodendrocyte progenitor marker NG2, and 20.2% for the
oligodendrocyte marker O1. These results are consistent
with data obtained from a brain precursor-derived neural
population in rats (Ben-Hur et al., 1998). It will be
interesting to determine if maGSC-derived neural precursor
cells are clonogenic and also if they consist of multipotent
NSCs or a mixture of more restricted neural progenitors
(McKay, 1997).
Furthermore we found that among all βIII-tubulin-positive
maGSC-derived neurons, 36.1% were positive for serotonin,
16% were positive for TH, and 14.5% were positive for
GAD65/67 in the Stage 5 cultures. These results indicate the
generation of specific subtypes, including serotonergic,
dopaminergic, and GABAergic neurons, after application of
Shh and FGF8b.Application of Shh and FGF8b yielded higher enrichment
of dopaminergic neurons from maGSC-derived precursors.
Subtype specification of differentiating neurons depends on
the interplay between the intrinsic signals required for
progenitor differentiation and the morphogens present in the
surrounding environment (Jessell, 2000). Although it is not
clear how dopaminergic and serotonergic fate specification
is controlled by intrinsic signals, the importance of Shh and
FGF8b in the differentiation process of dopaminergic and
serotonergic neurons from primary (Ye et al., 1998) and ESC-
derived neuroepithelia (Lee et al., 2000; Roy et al., 2006) has
been already demonstrated. In agreement with previous
findings (Lee et al., 2000) we found that the yield of TH-
positive cells was increased by 2-fold. Lee et al. reported a
14-fold increase in serotonin-positive neurons after a 6-day
induction of Shh/FGF8. However, we did not observe a
significant increase in serotonin-positive cells in the pre-
sence of FGF8b and Shh for 2 days. Further studies should be
performed to analyze the effects of long-term treatment
with Shh/FGF8b on the induction of TH- or serotonin-positive
neurons. Additional analysis to confirm that the TH-positive
cells are dopaminergic neurons should be done by showing
other markers of dopaminergic neurons, but the lack of
expression of the noradrenergic marker DBH. Furthermore,
dopamine release by TH-positive dopaminergic neurons
should be demonstrated before these cells can be considered
for therapeutic applications.
Electrophysiological recordings of passive and active
membrane properties and postsynaptic currents demonstrated
the maturation of maGSC-derived precursor cells into both
functional neurons and glial cells. Within 10 days of culture in
N2B27-I medium (Stage 5 cultures), maGSC-derived neurons
formed functional networks that were spontaneously active
and employed glutamatergic synaptic transmission for syn-
chronized oscillatory activity. Although our electrophysiologi-
cal data demonstrated that functional maturation of maGSC-
derived precursors can occur in culture, it is noteworthy that
many neural cells were still immature at Stage 5 (20.3% of the
cells were still positive for nestin and Sox1). In addition, 0.8%
of Stage 5 cells exhibited Oct3/4 immune reactivity.
Several previous studies described transplantation of
undifferentiated ESCs, as well as ESC-derived neural pro-
genitor cells or dopaminergic neurons, into experimental
models of Parkinson disease (Bjorklund et al., 2002; Kim et
al., 2002; Ben-Hur et al., 2004; Takagi et al., 2005; Thinyane
et al., 2005; Morizane et al., 2006; Roy et al., 2006). Whereas
transplantation of undifferentiated ESCs produced terato-
mas or highly malignant teratocarcinomas (Bjorklund et al.,
2002), some studies showed that transplantation of ESC-
derived neural progenitors, neuronal cells, or glial cells did
not produce brain tumors (Brustle et al., 1999; Kim et al.,
2002; Ben-Hur et al., 2004; Takagi et al., 2005; Yang et al.,
2008). In contrast, other studies demonstrated that even
minor contamination with undifferentiated ESCs or neural
progenitor cells promoted tumorigenesis (Thinyane et al.,
2005; Morizane et al., 2006; Roy et al., 2006). Therefore, it
will probably be necessary to isolate terminally differen-
tiated cells for future therapeutic applications. In this
regard, recent studies have shown that treatment with
ascorbic acid (a factor with strong neuroprotective activ-
ities), together with Shh and FGF8b, promoted dopaminergic
neuron differentiation significantly (more than 40-fold) from
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survival-promoting factors (namely, IL-1β, GDNF, NTN, TGF-
β3, and db-cAMP) during the terminal differentiation stages
significantly enhanced differentiation and viability of ESC-
derived dopaminergic neurons (Rolletschek et al., 2001).
In addition to dopaminergic cells, maGSCs were also able
to differentiate into other subtypes of specified neurons,
including glutamatergic, serotonergic, and GABAergic neu-
rons, as well as glial cells. Therefore, maGSC-derived neural
cells constitute a promising cell source for the treatment of
many different nervous system disorders. It is likely that
regeneration strategies developed previously for ESCs will be
directly applicable to maGSCs-derived neurons. Although
maGSC-derived neurons are functional in vitro, their
potential to engraft into the damaged host brain and
function as neurons after transplantation remains to be
demonstrated. In addition to their potential for autologous
cell therapy, the neural differentiation of maGSCs demon-
strated here provides new opportunities for basic research
on neural development as well as neural regeneration.
In conclusion, we have demonstrated that neural pro-
genitors, functional neurons, and glial cells can be derived
from maGSCs. These maGSC-derived cells can now be tested
for their ability to restore the function of damaged brains in
animal models. If successful, this would open new options in
organ regeneration without the ethical and immunological
problems associated with the ESC-based therapy.Materials and methods
Cell culture and in vitro differentiation of maGSCs
Mouse maGSCs (line SSC5) used in this study were derived
from Stra8-EGFP/Rosa26 transgenic mice as described pre-
viously (Guan et al., 2006). Expansion of undifferentiated
maGSCs was carried out by cultivation on mitomycin C-
inactivated MEFs isolated from 13.5- to 16.5-day-old
embryos (Wobus et al., 2002) in ESC medium: Dulbecco's
modified Eagle medium (DMEM; Invitrogen) supplemented
with 15% fetal calf serum (FCS; Invitrogen), 1× MEM-
nonessential amino acids (NEAA; Invitrogen), 50 μM β-
mercaptoethanol (β-ME; Promega), and 103 units/ml leuke-
mia inhibitory factor (ESGRO; Millipore) at 37 °C as described
(Guan et al., 2006).
Prior to neural differentiation of maGSCs, MEFs were
eliminated by using the preplating method. Briefly, cells
were trypsinized, replated on gelatin (0.1%; Fluka)-coated
dishes in culture medium, and incubated at 37 °C and in 5%
CO2. One hour after incubation, the MEFs attached the
culture dishes, and the floating maGSCs were then collected
and used for differentiation. For induction of neural
differentiation, maGSCs (typically 2.5×105 cells/dish) were
allowed to grow as cell aggregates in uncoated 6-cm
nonadherent bacteriological petri dishes (Greiner) in NSC
medium [DMEM/F12 with GlutaMAX (Invitrogen) supplemen-
ted with 1× N2 (Invitrogen), 1× NEAA, 50 μM β-ME, bFGF
(20 ng/ml; Tebu, Yvelines Cedex, France), and EGF (10 ng/
ml; Tebu)] (Ying and Smith, 2003) for 2 days. The cell
aggregates were collected and then plated onto 0.1% gelatin-
coated tissue culture plates (Nunc) in NSC medium with 2%
FCS for 24 h. Selection and proliferation of neural progenitorcells were achieved by culturing the cells in NSC medium for
10 to 18 days. For neural differentiation, neural progenitor
cells were cultivated in N2B27-I medium, the modified N2B27
medium (Ying and Smith, 2003) supplemented with bFGF
(20 ng/ml). The formulation of N2B27-I medium is DMEM/F12
with GlutaMAX supplemented with N2-I, the modified N2
[20 μg/ml insulin (Invitrogen), 20 μg/ml human apo-
transferrin (Sigma–Aldrich), 6.3 ng/ml progesterone
(Sigma), 16 μg/ml putrescine (Sigma), 30 nM sodium
selenite, and 50 μg/ml BSA (Invitrogen)], combined 1:1
with Neurobasal medium (Invitrogen) supplemented with 1×
B27 with vitamin A (Invitrogen), 1× L-glutamine (Sigma), and
50 μM β-ME. To induce specification of functional neurons,
the ventral midbrain patterning factors FGF8b (100 ng/ml;
R&D Systems) and Shh (400 ng/ml; R&D Systems) were added
to the N2B27-I medium for 2 days. The medium was changed
every 2 days up to 20 days, and bFGF was applied daily.
RNA extraction and RT-PCR analysis
Total RNAs of cultures at various differentiation stages were
prepared using the SV Total RNA isolation kit (Promega). Two
hundred nanograms of DNase-treated RNA was used for first-
strand cDNA synthesis by using murine leukemia virus reverse
transcriptase and oligo(dT)16 (Applied Biosystems). One-
tenth of each cDNA reaction was used as PCR template and
amplified for 34–46 cycles depending on the particular mRNA
abundance with denaturing at 94 °C for 15 s, annealing at 55
to 66 °C for 15 s according to the primers, and elongation at
72 °C for 30 s. Relative expression of the various mRNAs was
analyzed by normalizing the amount based on the signal from
ubiquitously expressed glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) mRNA. The primer sequences (forward
and reverse), the lengths of the amplified products, the
annealing temperatures, and the cycles used were as
follows: Oct3/4, 5′-GGCGTTCTCTTTGGAAAGGTGTTC-3′ and
5′-CTCGAACCACATCCTTCTCT-3′ (312 bp, 61 °C, 38 cycles);
Nanog, 5′-AGGGTCTGCTACTGAGATGCTCTG-3′ and 5′-CAAC-
CACTGGTTTTTCTGCCACCG-3′ (363 bp, 66 °C, 34 cycles);
Sox2, 5′-GGCGGCAACCAGAAGAACAG-3′ and 5′-GCTTGG-
CCTGCGTCGATGAAC-3′ (196 bp, 61 °C, 39 cycles); nestin,
5′-AGTGTGAAGGCAAAGATAGC-3′ and 5′-TCTGTCAAGATC-
GGGATGGG-3′ (311 bp, 55 °C, 39 cycles); Mash1, 5′-
CTCGTCCTCTCCGGAACTGATG-3 ′ and 5 ′-CGACAG-
GACGCCGCGCTGAAAG-3′ (301 bp, 64 °C, 38 cycles); syn,
5′-GCCTGTCTCCTTGAACACGAAC-3′ and 5′-TACCGA-
GAGAACAACAAAGGGC-3′ (287 bp, 60 °C, 37 cycles); Olig2,
5′-GGCGGTGGCTTCAAGTCATC-3′ and 5′-TAGTTTCGCGCCAG-
CAGCAG-3′ (250 bp, 61 °C, 39 cycles); GFAP, 5′-GAGGAGTGG-
TATCGGTCTAAGTTTG-3′ and 5′-GCCGCTCTAGGGACTCGTT-3′
(165 bp, 64 °C, 38 cycles); GLT1, 5′-AGAGGCTGCCCGTTAAA-
TACCG-3′ and 5′-GTAATACACCATAGCTCTCGC-3′ (473 bp,
57 °C, 40 cycles); SerT, 5′-GGATCCCTGCTCACACTG-3′ and
5′-GAATTCTTACACAGCATTCATGCG-3′ (473 bp, 59 °C, 38
cycles); GAD65, 5′-GGCTCTGGCTTTTGGTCCTTC-3′ and 5′-
TGCCAATTCCCAATTATACTCTTGA-3′ (438 bp, 56 °C, 40
cycles); TH, 5′-TGTCAGAGCAGCCCGAGGTC-3′ and 5′-CCAA-
GAGCAGCCCATCAAAG-3′ (412 bp, 64 °C, 39 cycles); D2R-L,
5′-GCAGTCGAGCTTTCAGAGCC-3′ and 5′-TCTGCGGCTCATCG-
TCTTAAG-3′ (404 bp, 58 °C, 39 cycles), and GAPDH, 5′-
GCAGTGGCAAAGTGGAGATT-3′ and 5′-TCTCCATGGTGGTGAA-
GACA-3′ (249 bp, 56 °C, 31 cycles).
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Cultures at different stages were fixed with 4% paraformal-
dehyde (Sigma) in PBS at room temperature for 20 min or
methanol/acetone (7/3) at −20 °C for 10 min and blocked
with 1% BSA at 4 °C overnight. Immunocytochemical staining
was carried out using standard protocols as previously
described (Wobus et al., 2002). The primary antibodies were
used at the following dilutions: Oct3/4 1:50 (goat polyclonal
antibody; R&D Systems), Ki67 1:50 (mouse monoclonal anti-
body, clone MIB-5; DakoCytomation), nestin 1:10 (mouse
monoclonal antibody, clone Rat-401; Developmental Hybri-
doma Bank), Sox1 1:500 (chicken polyclonal antibody;
Millipore), βIII-tubulin 1:500 (mouse monoclonal antibody,
clone TuJ1; BabCO), SNAP25 1:500/1:1000 (rabbit polyclonal
antibody; Sigma), serotonin 1:1000 (rabbit polyclonal anti-
body; Sigma), GAD65/67 1:10,000 (rabbit polyclonal antibody;
Sigma), TH 1:200 (rabbit polyclonal antibody; Pel-Freez),
GFAP 1:500 (mouse monoclonal antibody, clone GA5; Sigma),
O1 1:400 (mouse monoclonal antibody, clone 59; Millipore),
NG2 1:100 (rabbit polyclonal antibody; Millipore), DAT 1:500/
1:1000 (rabbit polyclonal antibody; Sigma), and DBH 1:500/
1:1000 (rabbit polyclonal antibody; Abcam). The primary
antibodies were applied for 1 h at 37 °C or overnight at 4 °C.
The fluorescently labeled secondary antibodies with minimal
cross-reactivity were Cy3-conjugated donkey anti-chicken IgY
(1:200, for Sox1), Cy3-conjugated goat anti-mouse IgG+IgM
(1:600, for O1), Cy3-conjugated goat anti-rabbit IgG (1:600,
for SNAP25, serotonin, GAD65/67, and TH), Cy3-conjugated
donkey anti-goat IgG (1:800, for Oct3/4), and FITC-conju-
gated goat anti-rabbit IgG (1:300, for NG2, DAT, and DBH) from
Dianova and Alexa Fluor 488 donkey anti-mouse IgG (1:200, for
Ki67, nestin, and βIII-tubulin) from Invitrogen. The secondary
antibodies were administered in 0.5% BSA for 1 h at 37 °C.
Samples were mounted with VectaShield mounting medium
containing DAPI (Vector Laboratories). Using antibodies
against Oct3/4, Ki67 and Sox1, the samples were initially
permeabilized by incubation in 0.2% Triton X-100 (Sigma) in
PBS for 10 min at room temperature.
The specificity controls for immunocytochemical methods
were included in this study as previously described (Burry,
2000). The specificity of the methods was determined by
including a negative control, replacing the primary antibody
with serum from the same species. Primary antibodies were
tested for their specificity by immunoblot before use. For
double immunostaining, to exclude the cross-reactivity of
second antibodies, controls were included. For example, for
double staining with nestin and Sox1 we used our neural
progenitor cultures at Stage 3. Two coverslips were given
nestin and Sox1 antibodies separately, but incubated with
both Alexa Fluor 488 donkey anti-mouse IgG (for nestin) and
Cy3-conjugated donkey anti-chicken IgY (for Sox1) together.
Similarly, we included controls to exclude the cross-
reactivity of Cy3-conjugated goat anti-rabbit IgG (for
serotonin, GAD65/67, and TH) and Alexa Fluor 488 donkey
anti-mouse IgG (for βIII-tubulin).
Images were analyzed using a fluorescence microscope
(Axiovert 200; Zeiss). Detection of the FITC and Alexa Fluor
488 fluorophores was performed by using the filter sets
with excitation BP 475/40, beam splitter FT 500, and
emission BP 530/50. Detection of the Cy3 fluorophore wasperformed by using the filter sets with excitation BP 540/
25, beam splitter FT 565, and emission BP 605/55. De-
tection of the DAPI fluorophore was performed by using the
filter sets with excitation G 365, beam splitter FT 395, and
emission BP 445/50. For quantitative analysis, cells in five
visual fields (using a 20× objective) were randomly selected
and counted from each coverslip. At least three indepen-
dent experiments were performed. Statistical analyses
were carried out using the Student t test (SigmaPlot/
SigmaStat software, SPSS, Inc.). Results were considered
significant if Pb0.05.
Electrophysiology
Mouse maGSC-derived neural populations were investigated
using whole-cell voltage and current-clamp recording tech-
niques. Neural progenitors were cultured on 12-mm glass
coverslips in N2B27-I medium with bFGF for 8–19 days. For
electrophysiological experiments coverslips were trans-
ferred to artificial cerebrospinal fluid (aCSF) containing the
following (in mM): 118 NaCl, 3 KCl, 1.5 CaCl2, 1 MgCl2, 30 D-
glucose, 1 NaH2PO4, and 25 NaHCO3, pH 7.4 (adjusted with
KOH); the osmolarity was 320–340 mOsm. The aCSF was
continuously exchanged at a rate of 3–5 ml/min. Experi-
ments were performed at room temperature. Whole-cell
recordings were obtained with an L/M-PCA patch-clamp
amplifier (E.S.F.) with borosilicate glass capillaries (Biome-
dical Instruments) with 2-μm outer diameter (resistance 3–
8 MΩ) pulled on a horizontal pipette puller (Zeitz Instru-
ments). Pipettes were filled with intracellular solution
containing (in mM) 125 KCl, 1 CaCl2, 2 MgCl2, 4 Na2ATP, 10
EGTA, and 10 Hepes, pH 7.2 (adjusted with KOH). Individual
recorded cells were documented by taking images with a CCD
camera (SensiCam) using Imaging Workbench 5.2 acquisition
software (Indec Biosystems).
Voltage- and current-step protocols were applied by the
L/M-PCA patch-clamp amplifier connected to a D/A–A/D
interface (ITC16, HEKA) controlled by Pulse software (v.8.77;
HEKA). Cells were voltage clamped to −70 mVand stepped to
potentials ranging from −150 to +40 mV in 10-mV increments
for electrophysiological characterization. To determine the
size of sodium currents an online P/4 leak subtraction mode
protocol was applied (Pulse software; leak holding potential
−120 mV). In parallel, spontaneous action potentials and
postsynaptic currents were digitized at 10 kHz (filtered at
3 kHz) using a PowerLab interface and Chart 5.5 software
(ADInstruments Pty Ltd). Data were stored on hard disk for
the offline analysis. For glutamate application we used a
pressure application system (PDES 02DX; NPI-Electronic). For
this, glutamate was dissolved at 100 mM in a Hepes-buffered
bath solution containing (in mM) 118 NaCl, 3 KCl, 1.5 CaCl2,
1 MgCl2, 25 Hepes, and 30 D-glucose, pH 7.4, and was placed
in a patch pipette (5 to 8 MΩ). Approximately 8 pl of the
solution was pressure ejected (1.6 bar, 50–100 ms) at a
distance of 30–50 μm from the recorded cell. The distance
was adjusted to prevent mechanical artifacts from the
ejected solution.
Data were analyzed offline with IGOR Pro (WaveMetrics)
and expressed as means ±standard error of the mean.
Student's t test was used to determine statistical significance
(SigmaPlot/SigmaStat software). Results were considered
significant if Pb0.05.
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